Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Oxybutynin hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Oxybutynin contains a medicine called oxybutynin hydrochloride. This belongs to two groups of medicines called 'anticholinergics' and 'antispasmodics'. It works by relaxing the muscles of the bladder and stops sudden muscle contractions (spasms). This helps control the release of water (urine). Oxybutynin can be used in adults and children 5 years or older to treat: loss of control in passing water (urinary incontinence) increased need or urgency to pass water (urine) night time bedwetting, when other treatments have not worked You must talk to a doctor if you do not feel better or if you feel worse.
e Oxybutynin Do not take Oxybutynin if: you are allergic to oxybutynin hydrochloride or any of the other ingredients of this medicine (listed in section 6). Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue. you have a rare muscle illness called 'Myasthenia gravis' you have increased pressure in the eye (glaucoma) your gut (stomach or intestine) is blocked, perforated or not working properly (intestinal atomy or intestinal occlusion, toxic megacolon) you have a severe form of a condition known as 'ulcerative colitis' you have a blockage that makes it difficult for you to pass water (urine). Do not take this medicine if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Oxybutynin.
Warnings and precautions Talk to your doctor or pharmacist before taking Oxybutynin if: you are 65 years of age or older you have certain heart conditions (deficiency congestive heart failure, coronary heart disease) the person taking the medicine is a child (use is not recommended under 5 years of age) you have brain problems (such as hallucinations, agitation, confusion, drowsiness) you have kidney or liver problems you have stomach or bowel problems (such as bowel obstruction, bowel laziness, inflammation of bowel) you have neurological disorders (such as Parkinson's disease) you have an illness affecting the nerves called 'autonomic neuropathy' you have eye problem (such as glaucoma) you have an overactive thyroid gland ('Hyperthyroidism') you have dental caries or a fungal infection in the mouth you have heart disease or high blood pressure you have an irregular heart beat (palpitations) and/or increased or rapid heart beat you have an enlarged prostate gland you have indigestion or heart burn caused by a 'hiatus hernia' (where part of your stomach pushes through the diaphragm) you have a raised body temperature or fever you will be taking this medicine in a hot climate you have long-term illness you have a urinary tract infection you have acid reflux in your mouth, sometimes responsible for digestive burns (gastrosoesophageal reflux disease) you are taking medicines (such as bisphosphonates) at the same time that may cause or exacerbate inflammation of the oesophagus. you urinate unintentionally after exertion During treatment
PIL/UK/MFG030/04/SMD/v5
Children 5 years of age and older: Children are more likely to have side effects. Therefore, oxybutynin should be used with caution in this age group. If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Oxybutynin. Other medicines and Oxybutynin Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, including herbal medicines. This is because Oxybutynin can affect the way some medicines work. Also some medicines can affect the way Oxybutynin work. In particular, tell your doctor if you are taking any of the following: Other anticholinergic or antimuscarinic medicines – such as some medicines for irritable bowel syndrome, asthma or incontinence, motion sickness or movement disorders associated with Parkinson's disease Some medicines used to treat dementia (e.g. donepezil, rivastigmine, galantamine or tacrine (cholinesterase inhibitors)) Some medicines for stomach and gut problems (e.g. domperidone, metoclopramide, bethanechol) CYP3A inhibitors (e.g. ketoconazole, itraconazole or fluconazole used to treat fungal infections or erythromycin, or other macrolide antibiotics used to treat bacterial infections) Medicines used to make you feel sleepy (sedatives) or if you are feeling sick (nausea) or have vertigo – such as prochlorperazine or chlorpromazine Medicines used to treat certain mental illnesses – such as clozapine, phenothiazines, haloperidol or benperidol (butyrophenones) Medicines for depression – such as amitriptyline, imipramine or dosulepin ('tricyclic antidepressants') and lithium Amantadine, biperiden, levodopa used in Parkinson's disease or to treat and prevent some viral infections Aminopenicillins, tetracyclines, sulfamethoxazole, cotrimoxazole drugs used for inhibition of bacterial infections Digoxin, quinidine, disopyr amide, procainamide and lidocaine – used to treat heart problems Dipyridamole – used to treat blood problems Antihistamines – used to treat allergies Paracetamol – used to treat pain Phenylbutazone – used to treat inflammation Atropine and related compounds drugs used for spasms of the digestive tract Oxybutynin with food, beverages and alcohol Alcohol may increase drowsiness caused by oxybutynin. Pregnancy, breast-feeding and fertility Talk to your doctor before taking this medicine if: You are pregnant, think you may be pregnant or are planning to have a baby. You should not take this medicine if you are pregnant without your doctor's advice. You are breast-feeding or planning to breast-feed. This is because small amounts may pass into mothers' milk. Breast feeding while using Oxybutynin is therefore not recommended. TURN OVER
Driving and using machines You may feel drowsy or have blurred vision while you are taking this medicine. If this happens, do not drive or use any tools or machines. Oxybutynin contains: Sorbitol (E420): This medicine contains 896mg sorbitol in each 5ml dose which is equivalent to 179.2mg/ml. Sorbitol is a source of fructose. If your doctor has told you that you (or your child) have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you (or your child) take or receive this medicine. Sorbitol may cause gastrointestinal discomfort and mild laxative effect. Methyl parahydroxybenzoate (E218): may cause allergic reactions (possibly delayed). Sodium: This medicine contains less than 1 mmol sodium (23 mg) per 5ml dose, that is to say essentially 'sodium-free'. Propylene glycol (E1520): This medicine contains 15.5mg propylene glycol in each 5ml dose which is equivalent to 3.1mg/ml.
Oxybutynin Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. The recommended doses are given below. These may be changed by your doctor: Adults The starting dose is 2.5 mg (5 ml) three times a day The usual dose is 5mg (10ml) two or three times a day Your doctor may decide to increase to the maximum dose of 5mg (10ml) four times a day Elderly The usual dose is 2.5mg (5ml) twice a day Your doctor may decide to increase this to 5mg (10ml) twice a day Children (over 5 years) The usual dose is 2.5mg (5ml) twice a day Your doctor may decide to increase this dose by weight to 0.3 or 0.4 mg/kg/day If you are giving it to a child to prevent bedwetting, give the last dose just before bedtime In some cases, your doctor may increase the dose to a maximum of: Age Standard dosage 5-9 years 2.5 mg (5 ml) 3 times daily 9-12 years 5 mg (10 ml) twice daily 12 years 5 mg (10 ml) 3 times daily and older Your doctor may review you after 4 to 6 weeks to assess the effectiveness of the treatment. Method of administration For oral use only Use the 2.5-5ml double-ended spoon supplied in the pack to measure the required dose (see figure below). Swallow the solution. Wash the spoon with clean water after taking every dose. 2.5 – 5ml double-ended Spoon
If you take more Oxybutynin than you should Contact your nearest hospital casualty department or tell your doctor immediately. Take the medicine pack PIL/UK/MFG030/04/SMD/v5
with you. This is so the doctor knows what you have taken. Taking too much Oxybutynin can be very dangerous. You may become very restless or excited, flushed or get dizzy or light-headed. You may have redness or your blood pressure may fall. Your heart beat may become very fast, uneven or forceful. You may get breathing problems or numbness or go into a coma. If you forget to take Oxybutynin If you forget a dose, take it as soon as you remember it. However, if it is nearly time for the next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose. If you stop taking Oxybutynin Keep taking Oxybutynin until your doctor tells you to stop. Do not stop taking Oxybutynin just because you feel better. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop taking Oxybutynin and contact your doctor immediately if you develop the following symptoms: You have an allergic reaction. The signs may include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue. You feel reduced sweating, leading to overheating in hot environments Other side effects: Very common: may affect more than 1 in 10 people Dry mouth, constipation, nausea Dizziness, headache, drowsiness Dry skin Blurred vision Common: may affect up to 1 in 10 people Diarrhoea, vomiting Confusional state Dry eyes Inability or difficulty in passing water (urine) Flushing Strong heartbeat which may be rapid or irregular. Uncommon: may affect up to 1 in 100 people Stomach pain, loss of appetite (anorexia), decrease appetite, difficulty in swallowing (dysphagia) Not known: cannot be estimated from the available data A bladder infection (Urinary tract infection) Indigestion or heartburn (acidreflux) Fits (convulsions) Agitation Seeing or hearing things that are not there (hallucinations), delirium Cognitive impairment (especially in the elderly) Nightmares A forceful heartbeat that may be rapid or irregular Enlargement of the pupil of the eye, increased pressure in the eyes (glaucoma), dry eyes Rash or skin that is more sensitive to the sun Anxiety Mental Health disorders Symptoms of depression Dependence on oxybutynin (in patients with a history of addiction to substances) Paranoia Shaking Allergic reaction Muscle weakness, muscle pain or cramps Nosebleed
Abnormal reduction in sweating (hypohidrosis) which can lead to heat stroke Intestinal motility disorders (obstruction) in some patients Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Oxybutynin Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP. The expiry date refers to the last day of that month. Do not store above 25°C. Discard 30 days after first opening. Store in the original packaging after first opening. Do not use this medicine if you notice that the solution becomes discoloured or shows any signs of deterioration. Seek the advice of your pharmacist. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Oxybutynin contains The active substance is oxybutynin hydrochloride. Each 5ml oral solution contains 2.5mg oxybutynin hydrochloride. The other ingredients are citric acid monohydrate (E330), sodium citrate (E331), liquid sorbitol (non-crystallising) (E420), glycerol (E422), methyl parahydroxybenzoate (E218), raspberry flavour (containing propylene glycol (E1520)) and purified water. What Oxybutynin looks like and contents of the pack Oxybutynin is a clear, colourless oral solution with raspberry odour and supplied in amber glass bottles with tamper evident, child resistant plastic cap and with a 2.5-5ml double ended spoon for measuring the dose. Oxybutynin hydrochloride 2.5mg/5ml oral solution is supplied in bottles containing 100ml and 150ml solution. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer: SyriMed, Unit 4, Bradfield Road, Ruislip, Middlesex, HA4 0NU, UK. POM If this leaflet is hard to see or read, please call +44 (0) 208 515 3700 for help. This leaflet was last revised in 03/2025.
Oxybutynin hydrochloride 2.5mg/5ml Oral Solution comes as oral solution containing 2.5mg / 5ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Oxybutynin hydrochloride 2.5mg/5ml Oral Solution is oxybutynin hydrochloride.
Medicines with the same active substance, strength and form include: Oxybutynin Hydrochloride 2.5 mg/5 ml Oral solution, Oxybutynin hydrochloride 2.5 mg/5 ml oral solution. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Oxybutynin hydrochloride 2.5mg/5ml Oral Solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Urinary incontinence, urgency and frequency in the unstable bladder, whether due to neurogenic bladder disorders (detrusor hyperreflexia) in conditions such as multiple sclerosis and spina bifida, or to idiopathic detrusor instability (motor urge incontinence).
Paediatric population
Oxybutynin hydrochloride is indicated in children over 5 years of age for:
- Urinary incontinence, urgency and frequency in unstable bladder conditions due to idiopathic overactive bladder or neurogenic bladder disorders (detrusor overactivity).
- Nocturnal enuresis associated with detrusor overactivity, in conjunction with non-drug therapy, when other treatment has failed.
Adults:
The starting dose is 2.5 mg (5 ml) three times a day, increased if necessary, to the minimum effective dose to achieve a satisfactory clinical response. The usual dose is 5 mg (10 ml) two or three times a day and the maximum dose is 5 mg four times a day.
Elderly (including frail elderly):
The elimination half-life is increased in the elderly. Therefore, a dose of 2.5mg (5ml) twice a day, particularly if the patient is frail, is likely to be adequate. This dose may be titrated upwards to 5mg (10ml) twice a day to obtain a clinical response provided that the side effects are tolerated.
Children (under 5 years of age):
Not recommended
Children (over 5 years of age):
The starting dose of 2.5 mg (5 ml) twice daily will be increased individually to the lowest effective dose to achieve a satisfactory clinical response.
The standard dosages and maximum dosages (0.3-0.4 mg/kg/day) are shown in the following table per age group:
Age
Standard dosage
5-9 years
2.5 mg (5 ml) 3 times daily
9-12 years
5 mg (10 ml) twice daily
12 years and older
5 mg (10 ml) 3 times daily
Method of administration
For oral administration.
Measure the prescribed dose with the 2.5-5ml double ended spoon provided in the pack.
- Hypersensitivity to oxybutynin or to any of the excipients listed in section 6.1
- Myasthenia gravis.
- Narrow-angle glaucoma or shallow anterior chamber.
- Gastrointestinal obstruction including paralytic ileus, intestinal atony.
- Patients with toxic megacolon, severe ulcerative colitis.
- Patients with bladder outflow obstruction where urinary retention may be precipitated.
- Pollakiuria and nocturia caused by heart failure or kidney disease
Treatment with oxybutynin should be evaluated after 4 to 6 weeks as normal bladder function may be restored in some patients.
Oxybutynin should not be used to treat urinary incontinence due to exercise.
Oxybutynin should be used with caution in the frail elderly and in children who may be more sensitive to the effects of the product and in patients with autonomic neuropathy (such as those with Parkinson's disease), vegetative neuropathy, hepatic or renal impairment, severe gastro-intestinal motility disorders, tachyarrhythmia and cerebrovascular failure (also see section 4.3).
Anticholinergics should be used with caution in elderly patients due to the risk of cognitive impairment.
Anticholinergic treatments should be used with caution in patients with hiatal hernia/gastro-oesophageal reflux flow and/or who are taking concomitant treatments (such as biphosphonates) that may cause or exacerbate oesophagitis.
Gastrointestinal disorders: Anticholinergic medicinal products may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders, intestinal atony and ulcerative colitis.
Oxybutynin may aggravate tachycardia (and thus hyperthyroidism, congestive heart failure, coronary heart disease, cardiac arrhythmias, tachycardia, hypertension), cognitive disorders and symptoms of prostatic hypertrophy.
Anticholinergic CNS effects (e.g. hallucinations, agitation, confusion, somnolence) have been reported; monitoring recommended especially in first few months after initiating therapy or increasing the dose; consider discontinuing therapy or reducing the dose if anticholinergic CNS effects develop.
Since oxybutynin can cause narrow-angle glaucoma, patients should be advised to contact a physician immediately if they are aware of a sudden loss of visual acuity or ocular pain.
Oxybutynin may reduce salivary secretions which could result in dental caries, parodontosis or oral candidiasis.
Anticholinergic medicinal products should be used with caution in patients who have hiatus hernia/gastro-oesophageal reflux and/or who are concurrently taking medicinal products (such as bisphosphonates) that can cause or exacerbate esophagitis.
In case of urinary tract infection, appropriate antibacterial treatment should be initiated.
Under high environmental temperature conditions, oxybutynin treatment can lead to a decrease in sweating and lead to an inadequate or inappropriate response of the thermoregulation mechanisms, resulting in the occurrence of heat stroke. This risk is increased in extreme ages (infant, child, elderly) and in the case of chronic pathology (especially cardiovascular, renal or neuro-psychiatric)
Oxybutynin dependence has been observed in patients with a history of drug dependence
Paediatric population
Oxybutynin hydrochloride is not recommended for use in children below age 5 years due to insufficient data on safety and efficacy.
There is limited evidence supporting the use of Oxybutynin in children with monosymptomatic nocturnal enuresis (not related to detrusor overactivity).
In children over 5 years of age, Oxybutynin hydrochloride should be used with caution as they may be more sensitive to the effects of the product, particularly the CNS and psychiatric adverse reactions.
Excipient Warnings
This product contains:
Methyl parahydroxybenzoate (E218): This may cause allergic reactions (possibly delayed).
Sorbitol (E420): This medicinal product contains 896mg sorbitol in each 5ml dose which is equivalent to 179.2mg/ml. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. Sorbitol may cause gastrointestinal discomfort and mild laxative effect.
Sodium: This medicinal product contains less than 1 mmol sodium (23 mg) per 5ml dose, that is to say essentially 'sodium-free'.
Propylene glycol (E1520): This medicinal product contains 15.5mg propylene glycol in each 5ml dose which is equivalent to 3.1mg/ml.
Care should be taken if other anticholinergic agents are administered together with Oxybutynin, as a potentiation of anticholinergic effects could occur.
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity, such as amantadine and other anticholinergic antiparkinsonian medicinal products (e.g. biperiden, levodopa), antihistamines, antipsychotics (e.g. phenothiazines, butyrophenones, clozapine), quinidine, digitalis, tricyclic antidepressants, atropine and related compounds like atropinic antispasmodics and dipyridamole.
By reducing gastric motility, oxybutynin may affect the absorption of other drugs.
Oxybutynin is metabolised by cytochrome P450 isoenzyme CYP 3A4. Concomitant administration with a CYP3A4 inhibitor can inhibit oxybutynin metabolism and increase oxybutynin exposure.
Oxybutynin may antagonise prokinetic therapies.
Concomitant use with cholinesterase inhibitors may result in reduced cholinesterase inhibitor efficacy.
Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents such as oxybutynin (see section 4.7).
Pregnancy
There are no adequate data from the use of Oxybutynin hydrochloride in pregnant women. Animal studies are insufficient with respect to effects on pregnancy, embryonic/foetal development, parturition or postnatal development. The potential risk for humans is unknown. Oxybutynin should not be used during pregnancy unless clearly necessary.
Breast-feeding
When oxybutynin is used during lactation, a small amount is excreted in the mother's milk. Use of oxybutynin during breast feeding is therefore not recommended.
As Oxybutynin hydrochloride oral solution may produce drowsiness or blurred vision, the patient should be cautioned regarding activities requiring mental alertness such as driving, operating machinery or performing hazardous work while taking this drug.
Adverse effects have been listed under headings of body systems and their frequencies as follows, where possible: very common (≥ 1 / 10), common (≥ 1 / 100 to <1 / 10), uncommon (≥ 1 /1000 to <1 / 100), rare (≥ 1 / 10, 000 to <1 / 1000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Table 1: Adverse effects and their frequencies:
Body systems
Very common
(≥1/10)
Common
(≥1/100 to <1/10)
Uncommon
(≥ 1 /1000 to <1 / 100)
Not known
Infections and infestations
-
-
-
urinary tract infection
Gastrointestinal disorders
constipation, nausea, dry mouth
diarrhoea, vomiting
abdominal discomfort, anorexia, decreased appetite, dysphagia
gastroesophageal reflux disease pseudo-obstruction in patients at risk (elderly or patients with constipation and treated with other drugs that reduce intestinal motility)
Psychiatric disorders
-
confusional state
-
agitation, anxiety, hallucinations, nightmares, paranoia, cognitive disorders (particularly in the elderly), delirium, depressive symptoms, dependence (in patients with a history of drug or substance abuse)
Nervous system disorders
dizziness, headache, somnolence
-
-
convulsions
Cardiac disorders
-
palpitation
-
tachycardia, arrhythmia,
Injury, poisoning and procedural complications
-
-
-
heat stroke
Eye disorders
Vision blurred
dry eyes
-
narrow-angle glaucoma, mydriasis, intraocular hypertension,
Renal and urinary disorders
-
urinary retention
-
urination disorder
Vascular disorders
-
flushing
-
-
Skin and subcutaneous tissue disorders
dry skin
redness of the face (more pronounced in children than in adults)
-
angioedema, rash, urticaria, hypohidrosis
Immune system disorders
-
-
-
hypersensitivity
Respiratory, thoracic and mediastinal disorders
-
-
-
epistaxis
Musculoskeletal and connective tissue disorders
-
-
-
Muscle weakness, myalgia and muscle spasms
Insions, poisonings and procedural complications
-
-
-
hyperthermia
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The symptoms of overdose (mydriasis, agitation or even psychotic disorders, sharp decrease in secretions, tachycardia, cutaneous flush) with oxybutynin progress from an intensification of the usual side effects of CNS disturbances (from restlessness and excitement to psychotic behaviour), circulation changes (flushing, fall in blood pressure, circulatory failure etc), respiratory failure, paralysis and coma.
Measures to be taken are:
1) Immediate gastric lavage
2) physostigmine by slow intravenous injection
Adults: 0.5 to 2.0mg of physostigmine by slow intravenous administration. Repeat after 5 minutes, if necessary up to a maximum total dose of 5mg.
Children: 30micrograms/kg of physostigmine by slow intravenous administration. Repeat after 5 minutes, if necessary up to a maximum total dose of 2mg.
Fever should be treated symptomatically with tepid sponging or ice packs.
In pronounced restlessness or excitation, diazepam 10mg may be given by intravenous injection, tachycardia may be treated by intravenous injection of propranolol and urinary retention can be managed by catheterisation.
In the event of progression of the curare- like effect to the paralysis of the respiratory muscles, mechanical ventilation will be required.
Ask anything about Oxybutynin hydrochloride 2.5mg/5ml Oral Solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.